Single Cell Precision Inc. is pleased to announce that it has received support through Springboard Atlantic’s IP Advantage – IP Strategy program. This initiative provides innovators across Atlantic Canada with access to specialized expertise in IP education and funding to help shape intellectual property strategies that protect discoveries and create pathways for commercialization.

For Single Cell Precision Inc., this support represents an important milestone in the company’s biomarker research and technology development. Establishing a strong IP strategy early is critical for ensuring scientific discoveries can be translated into solutions that improve patient outcomes through commercialization. The guidance and resources provided through this program will help the company evaluate its options, including patents, trade secrets, and licensing strategies, to safeguard its innovations and prepare for future partnerships.

“Support from Springboard Atlantic gives us the expertise and guidance to position our technologies for real-world impact,” said Dr. Paola Marignani. “Developing a thoughtful IP strategy now means we can focus on advancing science while protecting the value of our work for patients and partners.”